Sebia – Newborn haemoglobin disorders screening
Every day more and more newborns are screened worldwide for metabolic and endocrine disorders. Although screening for haemoglobin has a long history in some countries (USA or UK), in other countries it is a recent addition to their screening panels (Portugal; Germany).
The increase of haemoglobin disorders in regions that previously did not see them has raised awareness of the importance of screening for them in newborns.
Early screening has proven to be effective in improving the lives of babies by providing appropriate treatment and follow-up.
Key benefits of the NEONAT Hb kit
-
Ease of use
All the steps are managed automatically by the instrument; it is easy to operate and requires few maintenance procedures. -
Automatic result interpretation
Samples are automatically identified as normal or abnormal by the software, allowing laboratories to quickly detect and identify pathological results and quickly releasing non-pathological samples. -
Excellent resolution
Thanks to Sebia Capillarys’ high resolution haemoglobins separation, the instrument allows the display of a clear profile, enabling easy identification of abnormal haemoglobin variants (S, C, D and E…) as well as abnormalities arising from thalassemia (Hb H, Hb Bart’s). -
Early detection
Early detection of haemoglobin disorders allows appropriate treatment and follow up, improving the infant’s life while reassuring parents.
Test Principle
The NEONAT Hb kit is intended for the detection of normal haemoglobins (F and A) and abnormal hemoglobin (S, C, D, E and Bart’s) in blood from newborns collected on filter paper. This qualitative analysis is performed by capillary electrophoresis with the CAPILLARYS 3 DBS automated instrument.
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
